Research ExplorerPublicationsClinical Events with Edoxaban in South Korean and Taiwanese ...

Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice

Standard

Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice. / Choi, Eue-Keun; Lin, Wei-Shiang; Hwang, Gyo-Seung; Kirchhof, Paulus; De Caterina, Raffaele; Chen, Cathy; Unverdorben, Martin; Wang, Chun-Chieh; Kim, Young-Hoon.

In: J CLIN MED, Vol. 10, No. 22, 5337, 16.11.2021.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Choi, E-K, Lin, W-S, Hwang, G-S, Kirchhof, P, De Caterina, R, Chen, C, Unverdorben, M, Wang, C-C & Kim, Y-H 2021, 'Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice', J CLIN MED, vol. 10, no. 22, 5337. https://doi.org/10.3390/jcm10225337

APA

Choi, E-K., Lin, W-S., Hwang, G-S., Kirchhof, P., De Caterina, R., Chen, C., Unverdorben, M., Wang, C-C., & Kim, Y-H. (2021). Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice. J CLIN MED, 10(22), [5337]. https://doi.org/10.3390/jcm10225337

Vancouver

Choi E-K, Lin W-S, Hwang G-S, Kirchhof P, De Caterina R, Chen C et al. Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice. J CLIN MED. 2021 Nov 16;10(22). 5337. https://doi.org/10.3390/jcm10225337

Bibtex

@article{4117fcba42954e20affcd653ab9c4238,
title = "Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice",
abstract = "Edoxaban is approved for stroke prevention in nonvalvular atrial fibrillation (AF) patients in numerous countries. Outcome data are sparse on edoxaban treatment in AF patients from routine clinical practice, especially in Asian patients. Global ETNA (Edoxaban in rouTine cliNical prActice) is a noninterventional study that integrates data from patients from multiple regional registries into one database. Here, we report the 1-year clinical events from AF patients receiving edoxaban in South Korea and Taiwan. Clinical events assessed included bleeding, strokes, systemic embolic events, transient ischemic attacks (TIAs), and all-cause and cardiovascular death. Overall, 2677 patients (mean (range) age 72 (66-78) years, male 59.7%, mean CHA2DS2-VASc score ± standard deviation 3.1 ± 1.4) were treated with 60 or 30 mg edoxaban and had 1-year follow-up data. The annualized event rates for major bleeding and clinically relevant non-major (CRNM) bleeding were 0.78% and 0.47%, respectively. Annualized event rates for ischemic stroke and hemorrhagic stroke were 0.90% and 0.19%, respectively. Event rates for major and CRNM bleeding and rates of ischemic stroke and TIA were higher in Taiwanese patients than in Korean patients. Event rates were low and similar to those found in other studies of edoxaban in Korean and Taiwanese AF patients, thus supporting the safety and effectiveness of edoxaban in this population.",
author = "Eue-Keun Choi and Wei-Shiang Lin and Gyo-Seung Hwang and Paulus Kirchhof and {De Caterina}, Raffaele and Cathy Chen and Martin Unverdorben and Chun-Chieh Wang and Young-Hoon Kim",
year = "2021",
month = nov,
day = "16",
doi = "10.3390/jcm10225337",
language = "English",
volume = "10",
journal = "J CLIN MED",
issn = "2077-0383",
publisher = "MDPI AG",
number = "22",

}

RIS

TY - JOUR

T1 - Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice

AU - Choi, Eue-Keun

AU - Lin, Wei-Shiang

AU - Hwang, Gyo-Seung

AU - Kirchhof, Paulus

AU - De Caterina, Raffaele

AU - Chen, Cathy

AU - Unverdorben, Martin

AU - Wang, Chun-Chieh

AU - Kim, Young-Hoon

PY - 2021/11/16

Y1 - 2021/11/16

N2 - Edoxaban is approved for stroke prevention in nonvalvular atrial fibrillation (AF) patients in numerous countries. Outcome data are sparse on edoxaban treatment in AF patients from routine clinical practice, especially in Asian patients. Global ETNA (Edoxaban in rouTine cliNical prActice) is a noninterventional study that integrates data from patients from multiple regional registries into one database. Here, we report the 1-year clinical events from AF patients receiving edoxaban in South Korea and Taiwan. Clinical events assessed included bleeding, strokes, systemic embolic events, transient ischemic attacks (TIAs), and all-cause and cardiovascular death. Overall, 2677 patients (mean (range) age 72 (66-78) years, male 59.7%, mean CHA2DS2-VASc score ± standard deviation 3.1 ± 1.4) were treated with 60 or 30 mg edoxaban and had 1-year follow-up data. The annualized event rates for major bleeding and clinically relevant non-major (CRNM) bleeding were 0.78% and 0.47%, respectively. Annualized event rates for ischemic stroke and hemorrhagic stroke were 0.90% and 0.19%, respectively. Event rates for major and CRNM bleeding and rates of ischemic stroke and TIA were higher in Taiwanese patients than in Korean patients. Event rates were low and similar to those found in other studies of edoxaban in Korean and Taiwanese AF patients, thus supporting the safety and effectiveness of edoxaban in this population.

AB - Edoxaban is approved for stroke prevention in nonvalvular atrial fibrillation (AF) patients in numerous countries. Outcome data are sparse on edoxaban treatment in AF patients from routine clinical practice, especially in Asian patients. Global ETNA (Edoxaban in rouTine cliNical prActice) is a noninterventional study that integrates data from patients from multiple regional registries into one database. Here, we report the 1-year clinical events from AF patients receiving edoxaban in South Korea and Taiwan. Clinical events assessed included bleeding, strokes, systemic embolic events, transient ischemic attacks (TIAs), and all-cause and cardiovascular death. Overall, 2677 patients (mean (range) age 72 (66-78) years, male 59.7%, mean CHA2DS2-VASc score ± standard deviation 3.1 ± 1.4) were treated with 60 or 30 mg edoxaban and had 1-year follow-up data. The annualized event rates for major bleeding and clinically relevant non-major (CRNM) bleeding were 0.78% and 0.47%, respectively. Annualized event rates for ischemic stroke and hemorrhagic stroke were 0.90% and 0.19%, respectively. Event rates for major and CRNM bleeding and rates of ischemic stroke and TIA were higher in Taiwanese patients than in Korean patients. Event rates were low and similar to those found in other studies of edoxaban in Korean and Taiwanese AF patients, thus supporting the safety and effectiveness of edoxaban in this population.

U2 - 10.3390/jcm10225337

DO - 10.3390/jcm10225337

M3 - SCORING: Journal article

C2 - 34830618

VL - 10

JO - J CLIN MED

JF - J CLIN MED

SN - 2077-0383

IS - 22

M1 - 5337

ER -